April 11, 2017 wallstreetnation
Biotech & Pharma

AZRX releases big update news on Tuesday

AzurRx Provides Update on MS1819 Phase II Trial GlobeNewswire•April 11, 2017 Comment Initial patient experience shows no safety issues MS1819 appears active, as demonstrated by CFA increases >20% at various dosing levels BROOKLYN, N.Y., April 11, 2017 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of … Continue reading “AZRX releases big update news on Tuesday”

Featured

Here’s the TOP Marijuana Stock You Haven’t Heard Of….YET!

The CANNABIS GREEN RUSH in on in Europe. The enormous volume of cash going into…

February 28, 2017 wallstreetnation